SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

The Albany County Genealogical Society monthly meeting is scheduled for 6 p.m. Tuesday, March 10, in the Relief Society Room at the Church of Jesus Christ of Latter-day Saints, located at 3311 Hayford ...

A peer-reviewed study published in Air Quality, Atmosphere and Health on February 26, 2026, reports that average serum ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 ...